直接抗病毒药物治疗HCV相关肝硬化的效果及安全性

游国琼; 王丽; 段萌; 朱鹏

doi:10.3969/j.issn.1001-5256.2019.01.041

直接抗病毒药物治疗HCV相关肝硬化的效果及安全性

DOI: 10.3969/j.issn.1001-5256.2019.01.041

1. 成都市公共卫生临床医疗中心肝病二科
2. 遂宁市第一人民医院消化内科

基金项目:

四川省卫生和计划生育委员会科研课题(18PJ343)；

详细信息

中图分类号: R575.2;R512.63
计量
- 文章访问数: 1191
- HTML全文浏览量: 51
- PDF下载量: 333
- 被引次数: 0
出版历程
- 出版日期: 2019-01-20

Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis

Second Department of Hepatology, Chengdu Public Health Medical Center, Chengdu 610000, China

Research funding:

摘要

摘要:
肝硬化在临床上十分常见,也是包括慢性HCV感染在内的多种慢性肝病的共同临床结局。在直接抗病毒药物（DAA）出现前,基于PEG-IFN及利巴韦林（RBV）的抗HCV治疗常由于肝硬化的存在而疗效不佳,甚至失代偿期肝硬化本身即是应用PEG-IFN治疗的绝对禁忌证。DAAs已逐渐成为临床治疗HCV感染的一线药物,大量研究显示DAAs用于HCV相关肝硬化患者的治疗具有良好的疗效及耐受度。一方面,DAAs治疗代偿期肝硬化患者的疗效及安全性均要优于PEG-IFN/RBV;另一方面,肝硬化失代偿患者也可耐受DAAs治疗,虽然获得的持续病毒学应答比例可能较普通患者更低,但是DAAs仍能使肝硬化失代偿患者在多方面获益。综述了DAAs用于治疗HCV相关肝硬化患者的最新研究,以求为临床诊治提供参考。
- 肝炎病毒属 /
- 肝硬化 /
- 抗病毒药 /
- 治疗学 /
- 综述
Abstract:
Liver cirrhosis is common in clinical practice and is the common clinical outcome of various chronic liver diseases including chronic hepatitis C virus (HCV) infection.Before the development of direct-acting antiviral agents (DAAs) , anti-HCV therapy based on pegylated interferon (PEG-IFN.) and ribavirin (RBV) has a poor clinical effect due to the presence of liver cirrhosis, and decompensated liver cirrhosis itself is an absolute contraindication for PEG-IFN treatment.DAAs have gradually become the first-line drug for HCV infection, and many studies have shown that DAAs have good clinical effects and tolerability in the treatment of cirrhotic patients with HCV infection.On the one hand, DAAs have better clinical effect and safety than PEG-IFN/RBV in patients with compensated liver cirrhosis;on the other hand, patients with decompensated liver cirrhosis are tolerant to DAAs, and although they have a lower proportion of patients with sustained virologic response than normal patients, they can still benefit from DAAs from many aspects.This article reviews the latest research advances in DAAs in patients with HCV-related liver cirrhosis, in order to provide a reference for clinical diagnosis and treatment.
- hepacivirus /
- liver cirrhosis /
- antiviral agents /
- therapeutics /
- review

HTML全文

参考文献(30)

[1]MOOSAVY SH, DAVOODIAN P, NAZARNEZHAD MA, et al.Epidemiology, transmission, diagnosis, and outcome of hepatitis Cvirus infection[J].Electr Physic, 2017, 9 (10) :5646-5656.

[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[3]MOROZOV VA, LAGAYE S.Hepatitis C virus:Morphogenesis, infection and therapy[J].World J Hepatol, 2018, 10 (2) :186-212.

[4]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol, 2018, 69 (2) :461-511.

[5]HUANG Y, LI MH, HOU M, et al.Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals[J].Hepatobiliary Pancreat Dis Int, 2017, 16 (5) :470-479.

[6]SPENGLER U.Direct antiviral agents (DAAs) -A new age in the treatment of hepatitis C virus infection[J].Pharmacol T-her, 2018, 183:118-126.

[7]BROWN A, HEZODE C, ZUCKERMAN E, et al.Efficacy and safety of 12 weeks of elbasvir±grazoprevir±ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection:The C-SCAPE study[J].J Viral Hepat, 2018, 25 (5) :457-464.

[8]SPERL J, HORVATH G, HALOTA W, et al.Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin:A phase III randomized controlled trial[J].J Hepatol, 2016, 65 (6) :1112-1119.

[9]KWO P, GANE EJ, PENG CY, et al.Effectiveness of Elbasvir and Grazoprevir combination, with or without Ribavirin, for treatment-experienced patients with chronic hepatitis C infection[J].Gastroenterology, 2017, 152 (1) :164-175.e164.

[10]ASSELAH T, REESINK H, GERSTOFT J, et al.Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection:A pooled analysis[J].Liver Int, 2018, 38 (9) :1583-1591.

[11]CORMAN S, ELBASHA EH, MICHALOPOULOS SN, et al.Costutility of Elbasvir/Grazoprevir in patients with chronic hepatitis Cgenotype 1 infection[J].Value Health, 2017, 20 (8) :1110-1120.

[12]MAUGHAN A, OGBUAGU O.Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection[J].Expert Opin Drug Metab Toxicol, 2018, 14 (2) :219-227.

[13]JACOBSON IM, GORDON SC, KOWDLEY KV, et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med, 2013, 368 (20) :1867-1877.

[14]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl JMed, 2013, 368 (20) :1878-1887.

[15]KUMADA H, SUZUKI Y, IKEDA K, et al.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J].Hepatology, 2014, 59 (6) :2083-2091.

[16]ZEUZEM S, DUSHEIKO GM, SALUPERE R, et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med, 2014, 370 (21) :1993-2001.

[17]LAWITZ E, SULKOWSKI MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:The COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.

[18]ZHAO XT, NIE QH.Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J].J Clin Hepatol, 2017, 33 (6) :1067-1072. (in Chinese) 赵西太, 聂青和.直接抗病毒药物治疗丙型肝炎的毒副作用、药物相互作用及安全性[J].临床肝胆病杂志, 2017, 33 (6) :1067-1072.

[19]PREDA CM, POPESCU CP, BAICUS C, et al.Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis[J].Liver Int, 2018, 38 (4) :602-610.

[20]FOSTER GR, AGARWAL K, CRAMP ME, et al.Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis:A randomized trial[J].Hepatology, 2018, 67 (6) :2113-2126.

[21]JACOBSON IM, LAWITZ E, KWO PY, et al.Safety and efficacy of Elbasvir/Grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis:An integrated analysis[J].Gastroenterology, 2017, 152 (6) :1372-1382.e1372.

[22]RAVAIOLI F, CONTI F, BRILLANTI S, et al.Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals[J].Dig Liver Dis, 2018, 50 (6) :573-579.

[23]CALVARUSO V, CABIBBO G, CACCIOLA I, et al.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents[J].Gastroenterology, 2018, 155 (2) :411-421.e4.

[24]European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.

[25]BELLI LS, DUVOUX C, BERENGUER M, et al.ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients[J].J Hepatol, 2017, 67 (3) :585-602.

[26]SORIANO V, BARREIRO P, de MENDOZA C, et al.Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis[J].Antivir Ther, 2016, 21 (1) :91-92.

[27]LIONETTI R, CALVARUSO V, PICCOLO P, et al.Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis:A prospective study[J].Clin Transplant, 2018, 32 (2) :e13165.

[28]MANNS M, SAMUEL D, GANE EJ, et al.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:A multicentre, open-label, randomised, phase 2 trial[J].Lancet Infect Dis, 2016, 16 (6) :685-697.

[29]CHARLTON M, EVERSON GT, FLAMM SL, et al.Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease[J].Gastroenterology, 2015, 149 (3) :649-659.

[30]CHENG DY, LIU XM, OU MN, et al.Clinical efficacy of directacting antiviral agents in patients with HCV-related liver cirrhosis[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :545-549. (in Chinese) 程丹颖, 刘晓民, 欧蔚妮, 等.直接抗病毒药物治疗丙型肝炎肝硬化的疗效观察[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :545-549.

施引文献

资源附件(0)

访问统计